Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion

BMC Neurology

Research

Mengyi Xu¹  Jie Yang²  Jianjun Zou³  Yuxiang Fei³  Xiding Pan⁴  Yapeng Lin⁵  Shiteng Lin⁶ 

[1] Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;Department of Neurology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, 32 Second Section of Yihuanxi Road, Chengdu, China;Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, China;Department of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China;Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, China;Department of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China;Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;International Clinical Research Center & Department of Neurology, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, China;School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China;

关键词: Vertebrobasilar artery occlusion;    Antiplatelet;    Tirofiban;    Mechanical thrombectomy;   

DOI  :  10.1186/s12883-022-02996-5

 received in 2022-05-11, accepted in 2022-11-30,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundEven undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality. Tirofiban is a novel antiplatelet agent which is now widely empirically used in acute ischemic stroke (AIS). In this study, we aimed to evaluate the safety and efficacy of tirofiban as adjunctive therapy for MT in AVBAO.MethodsFrom October 2016 to July 2021, consecutive AVBAO patients receiving MT were included in the prospective stroke registry. The short-term outcomes were (1) symptomatic intracerebral hemorrhage (sICH); (2) in-hospital death; (3) National Institute of Health Stroke Scale (NIHSS) at discharge. The Long-term outcomes were: (1) modified Rankin Scale (mRS) at 3 months; (2) death at 3 months.ResultsA total of 130 eligible patients were included in the study, 64 (49.2%) patients received tirofiban. In multivariate regression analysis, no significant differences were observed in all outcomes between the tirofiban and non-tirofiban group [sICH (adjusted OR 0.96; 95% CI, 0.12–7.82, p = 0.97), in-hospital death (adjusted OR 0.57; 95% CI, 0.17–1.89, p = 0.36), NIHSS at discharge (95% CI, -2.14–8.63, p = 0.24), mRS (adjusted OR 1.20; 95% CI, 0.40–3.62, p = 0.75), and death at 3 months (adjusted OR 0.83; 95% CI, 0.24–2.90, p = 0.77)].ConclusionsIn AVBAO, tirofiban adjunctive to MT was not associated with an increased risk of sICH. Short-term (in-hospital death, NIHSS at discharge) and long-term outcomes (mRS and death at 3 months) seem not to be influenced by tirofiban use.

【 授权许可】

CC BY   
© The Author(s) 2022. corrected publication 2022